Gaboxadol

Gaboxadol
Clinical data
ATC code	none;
Identifiers
	IUPAC name 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3(2H)-one;
CAS Number	64603-91-4 ;
PubChem CID	3448;
IUPHAR/BPS	4322;
ChemSpider	3330 ;
UNII	K1M5RVL18S;
KEGG	D04282 ;
ChEMBL	ChEMBL312443 ;
CompTox Dashboard (EPA)	DTXSID0045206 ;
ECHA InfoCard	100.059.039
Chemical and physical data
Formula	C6H8N2O2
Molar mass	140.142 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1/C2=C(\ON1)CNCC2;
	InChI InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9) ; Key:ZXRVKCBLGJOCEE-UHFFFAOYSA-N ;
	(what is this?) (verify)

Gaboxadol, also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP), is a conformationally constrained derivative of the alkaloid muscimol that was first synthesized in 1977 by the Danish chemist Poul Krogsgaard-Larsen.^[1] In the early 1980s gaboxadol was the subject of a series of pilot studies that tested its efficacy as an analgesic and anxiolytic, as well as a treatment for tardive dyskinesia, Huntington's disease, Alzheimer's disease, and spasticity.^[1] It was not until 1996 that researchers attempted to harness gaboxadol's frequently reported sedative "adverse effect" for the treatment of insomnia, resulting in a series of clinical trials sponsored by Lundbeck and Merck.^[1]^[2] In March, 2007, Merck and Lundbeck cancelled work on the drug, citing safety concerns and the failure of an efficacy trial. It acts on the GABA system, but in a different way from benzodiazepines, Z-Drugs, and barbiturates. Lundbeck states that gaboxadol also increases deep sleep (stage 4). Unlike benzodiazepines, gaboxadol does not demonstrate reinforcement in mice or baboons despite activation of dopaminergic neurons in the ventral tegmental area.^[3]

In 2015, Lundbeck sold its rights to the molecule to Ovid Therapeutics, whose plan is to develop it for FXS and Angelman syndrome.^[4] It is known internally in Ovid as OV101.

Pharmacology

Gaboxadol is a supra-maximal agonist at α4β3δ GABA_A receptors, low-potency agonist at α1β3γ2, and partial agonist at α4β3γ.^[5]^[6] Its affinity for this α4-containing subtype of the GABA_A receptor is 10× greater than other non-α4 containing subtypes.^[7] Gaboxadol also has a unique affinity for extrasynaptic GABA_A receptors, which desensitize more slowly and less extensively than synaptic GABA_A receptors.^[8]

References

^ ^a ^b ^c Morris H (August 2013). "Gaboxadol". Harper's Magazine. Retrieved 2014-11-20.
^ US 4278676, Krogsgaard-Larsen P, "Heterocyclic compounds", issued 14 July 1981, assigned to H Lundbeck AS
^ Vashchinkina E, Panhelainen A, Vekovischeva OY, Aitta-aho T, Ebert B, Ator NA, et al. (April 2012). "GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons". The Journal of Neuroscience. 32 (15): 5310–20. doi:10.1523/JNEUROSCI.4697-11.2012. PMC 6622081. PMID 22496576.
^ Tirrell M (16 April 2015). "Former Teva CEO's new gig at Ovid Therapeutics". CNBC. Retrieved 2015-05-06.
^ Brown N, Kerby J, Bonnert TP, Whiting PJ, Wafford KA (August 2002). "Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors". British Journal of Pharmacology. 136 (7): 965–974. doi:10.1038/sj.bjp.0704795. PMC 1573424. PMID 12145096.
^ Orser BA (2006-04-15). "Extrasynaptic GABAA Receptors Are Critical Targets for Sedative-Hypnotic Drugs". Journal of Clinical Sleep Medicine. 02 (2). doi:10.5664/jcsm.26526. ISSN 1550-9389.
^ Rudolph U, Knoflach F (July 2011). "Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes". Nature Reviews. Drug Discovery. 10 (9): 685–697. doi:10.1038/nrd3502. PMC 3375401. PMID 21799515.
^ Orser BA (April 2006). "Extrasynaptic GABAA receptors are critical targets for sedative-hypnotic drugs". Journal of Clinical Sleep Medicine. 2 (2): S12–8. doi:10.5664/jcsm.26526. PMID 17557502.

External links

4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
H. Lundbeck Website
Medical News Today article
Report of cancellation of development.
Gaboxadol

This sedative-related article is a stub. You can help Wikipedia by expanding it.

[Hamilton-1] Morris H (August 2013). "Gaboxadol". Harper's Magazine. Retrieved 2014-11-20.

[2] US 4278676, Krogsgaard-Larsen P, "Heterocyclic compounds", issued 14 July 1981, assigned to H Lundbeck AS

[3] Vashchinkina E, Panhelainen A, Vekovischeva OY, Aitta-aho T, Ebert B, Ator NA, et al. (April 2012). "GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons". The Journal of Neuroscience. 32 (15): 5310–20. doi:10.1523/JNEUROSCI.4697-11.2012. PMC 6622081. PMID 22496576.

[CNBC-4] Tirrell M (16 April 2015). "Former Teva CEO's new gig at Ovid Therapeutics". CNBC. Retrieved 2015-05-06.

[5] Brown N, Kerby J, Bonnert TP, Whiting PJ, Wafford KA (August 2002). "Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors". British Journal of Pharmacology. 136 (7): 965–974. doi:10.1038/sj.bjp.0704795. PMC 1573424. PMID 12145096.

[6] Orser BA (2006-04-15). "Extrasynaptic GABAA Receptors Are Critical Targets for Sedative-Hypnotic Drugs". Journal of Clinical Sleep Medicine. 02 (2). doi:10.5664/jcsm.26526. ISSN 1550-9389.

[7] Rudolph U, Knoflach F (July 2011). "Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes". Nature Reviews. Drug Discovery. 10 (9): 685–697. doi:10.1038/nrd3502. PMC 3375401. PMID 21799515.

[pmid17557502-8] Orser BA (April 2006). "Extrasynaptic GABAA receptors are critical targets for sedative-hypnotic drugs". Journal of Clinical Sleep Medicine. 2 (2): S12–8. doi:10.5664/jcsm.26526. PMID 17557502.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

Pharmacology

See also

References

External links